{"id":"evarrest","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Infection at application site"},{"rate":null,"effect":"Hematoma"}]},"_chembl":null,"_dailymed":{"setId":"92371a00-4bbd-4815-86dd-bae1505d0c2f","title":"EVARREST (FIBRINOGEN HUMAN AND HUMAN THROMBIN) PATCH [ETHICON, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EVARREST is a composite hemostatic patch containing human thrombin and human fibrinogen that works by mimicking the final steps of the coagulation cascade. When applied to bleeding surfaces, the thrombin activates fibrinogen to form fibrin, creating a stable clot that adheres to the tissue. This provides rapid hemostasis without requiring systemic absorption.","oneSentence":"EVARREST is a topical hemostatic agent that combines thrombin and fibrinogen to form a stable clot at the surgical site.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:52:32.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemostasis in surgical procedures where bleeding control is needed"}]},"trialDetails":[{"nctId":"NCT06793748","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer","status":"NOT_YET_RECRUITING","sponsor":"Rion Inc.","startDate":"2025-06","conditions":"Chronic Radiation Ulcer","enrollment":184},{"nctId":"NCT04602689","phase":"NA","title":"Fibrin Glue After ESD for High Risk Patients of Bleeding","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-10-30","conditions":"Early Gastric Cancer, Gastric Adenoma","enrollment":134},{"nctId":"NCT02227992","phase":"PHASE3","title":"The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2014-07-01","conditions":"Hemorrhage, Soft Tissue Bleeding, Hepatic Parenchyma Bleeding","enrollment":40},{"nctId":"NCT02117349","phase":"PHASE2","title":"Topical Raplixa for Surgical Bleeding in Children","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2014-12-04","conditions":"Surgical Bleeding","enrollment":55},{"nctId":"NCT02837484","phase":"NA","title":"NuTech Affinity™ for the Treatment of Chondral Defects","status":"UNKNOWN","sponsor":"NuTech Medical, Inc","startDate":"2016-05","conditions":"Chondral Lesions, Cartilage","enrollment":10},{"nctId":"NCT01527357","phase":"PHASE3","title":"A Study of Fibrocaps™ in Surgical Bleeding","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2012-05-21","conditions":"Mild or Moderate Surgical Bleeding","enrollment":721},{"nctId":"NCT01226914","phase":"NA","title":"A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2010-06","conditions":"Thyroid Neoplasm, Goiter","enrollment":55},{"nctId":"NCT01681030","phase":"PHASE2","title":"The Fibrin Pad Cardiovascular Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2012-08-01","conditions":"Cardiovascular Disease","enrollment":42},{"nctId":"NCT01902459","phase":"PHASE4","title":"EVARREST™ Fibrin Sealant Patch Post-Market Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2013-07-01","conditions":"Hemorrhage, Soft Tissue Bleeding","enrollment":150},{"nctId":"NCT01256164","phase":"NA","title":"U.S. Study of Fibrocaps in Surgical Hemostasis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2010-12","conditions":"Postoperative Hemorrhage","enrollment":70},{"nctId":"NCT02040428","phase":"PHASE3","title":"The Fibrin Pad CV Phase III Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2014-01-01","conditions":"Cardiovascular Disease","enrollment":156},{"nctId":"NCT01256190","phase":"PHASE2","title":"A Study of Fibrocaps in Liver Surgery in the Netherlands","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2010-12","conditions":"Postoperative Hemorrhage","enrollment":56},{"nctId":"NCT01158261","phase":"","title":"The Evicel Post-Authorization Surveillance Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2010-06","conditions":"Peripheral Vascular Disease, Hemorrhage","enrollment":300},{"nctId":"NCT01538927","phase":"PHASE4","title":"Effect of Fibrin Sealant on Early Wound Healing","status":"COMPLETED","sponsor":"Chhattisgarh Dental College and Research Institute","startDate":"2012-04","conditions":"Periodontitis","enrollment":15},{"nctId":"NCT00324272","phase":"PHASE4","title":"Post-Operative Drainage Following Lymph Node Dissection","status":"COMPLETED","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2003-01","conditions":"Malignant Melanoma, Carcinoma, Squamous Cell","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"EVARREST™","genericName":"EVARREST™","companyName":"Ethicon, Inc.","companyId":"ethicon-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"EVARREST is a topical hemostatic agent that combines thrombin and fibrinogen to form a stable clot at the surgical site. Used for Hemostasis in surgical procedures where bleeding control is needed.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}